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The Kidney Disease Outcomes Quality Initiative (K/DOQI)
guidelines recommend that serum parathyroid hormone
(PTH) concentration of patients with chronic kidney disease
(CKD) should be measured regularly and maintained within
target ranges that are defined according to the stage of CKD
(e.g., 150–300pg/ml in patients with CKD stage 5). The quality
of the PTH assay is of paramount importance, as it
contributes to the therapeutic decision. Indeed, when the
PTH concentration is above these target values, drugs that
decrease PTH secretion, such as active vitamin D compounds
or calcimimetic agents, may be given and the doses are then
adapted according to the evolution of the PTH concentration.
By contrast, if the PTH concentration is below the target
range, any treatment that may decrease PTH secretion is
stopped to avoid adynamic bone disease and associated
extra-skeletal calcifications. The aim of this article is to
discuss the main features and pitfalls related to PTH
measurement in the setting of CKD.
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Parathyroid hormone (PTH) is a single-chain 84-amino-acid
peptide hormone encoded by a gene on the short arm of
chromosome 11 and produced by the parathyroid glands in
response to a decrease in the extracellular concentration of
ionized calcium (Caþ þ ). Its half-life is very short (2–4 min)
and its main role is to increase serum Caþ þ , which is
achieved by stimulating the release of calcium from bone and
its renal re-absorption in the distal tubule. In the renal
proximal tubule, PTH also stimulates the synthesis of
calcitriol which in turn increases intestinal absorption
of calcium and exerts an endocrine feed-back on the secretion
of PTH at the parathyroid level. PTH also decreases the renal
re-absorption of phosphate in the proximal tubule, thereby
decreasing serum phosphate. Furthermore, PTH stimulates
bone formation, and this property is now used in clinical
practice for treatment of osteoporosis. It has been demon-
strated that the very first N-terminal amino acids of the PTH
molecule are indispensable for this interaction. Besides full-
length 1–84 PTH, various PTH fragments are present in
blood, whose exact composition and possible function are
not yet fully elucidated.
Apart from the well-known bone and renal effects, PTH
also acts in a number of other cells, such as the
cardiomyocyte, adipocyte, pancreas beta cell, among others.
The dysfunction of these cells or tissues observed in response
to an increase in serum PTH has led to the concept of PTH
being a uremic toxin.1–3
The Kidney Disease Outcomes Quality Initiative
(K/DOQI) for bone metabolism and disease in chronic
kidney disease (CKD) guidelines4 recommend that serum
PTH concentration of patients with CKD should be
measured regularly and maintained within target ranges that
are defined according to the stage of CKD (i.e., 150–300 pg/ml
in patients with CKD stage 5). The quality of the PTH assay is
of paramount importance as it contributes to the therapeutic
decision. Indeed, when the PTH concentration is above these
target values, drugs that decrease PTH secretion such as
active vitamin D compounds or calcimimetic agents may be
given and the doses are then adapted according to the
evolution of the PTH concentration. By contrast, if the PTH
concentration is below the target range, any treatment that
may decrease PTH secretion is stopped to avoid adynamic
bone disease and associated extra-skeletal calcifications. The
aim of this study is to discuss the main features and pitfalls
related to PTH measurement in the setting of CKD.
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THE DIFFERENT PTH ASSAYS AND WHAT THEY MEASURE
First-generation PTH assays were radioimmunoassays5 using
polyclonal antibodies directed mainly toward synthetic
C-terminal (such as 53–84 PTH) or mid-region (such as
44-68 PTH) PTH fragments. In addition to PTH 1–84, these
assays were known to measure fragments, which are mainly
produced in the liver by the catabolism in the Kupffer cells,
are eliminated by the kidney, have a longer half-life than 1–84
PTH, and accumulate in CKD patients.6 The consequence
was that, in CKD patients PTH concentrations measured
with these first-generation assays were always greatly
increased. Furthermore, these assays had poor analytical
sensitivity in the low concentrations, rendering discrimina-
tion between low and normal levels difficult. For these
reasons, the first-generation PTH assays are currently
considered obsolete for the clinical practice. During the
mid 1980’s, the first second-generation PTH assay, the
Allegro intact PTH assay, became available.7 This immunor-
adiometric assay used two different antibodies. The capture
antibody coated to a plastic bead was directed toward the
39–84 portion of the PTH molecule, whereas the 125-I-
labeled antibody recognized mainly the 15–20 portion of the
PTH molecule.8 This assay was, thus, unable to measure the
C-terminal or mid-fragments (such as 53–84 or 44–68),
which were measured with the first-generation assays. During
the following years, several similar assays, either immunor-
adiometric assay or ‘non-radioactive’ immunometric assays,
became available,9–11 some of them using fully automated
immunoanalyzers allowing better analytical performances
and shorter turnaround time.12,13 Some of these assays use an
anti-N-terminal antibody directed, like in the Allegro assay,
toward the proximal 15–20 portion of the hormone, whereas
others, like the Elecsys/Modular intact PTH assay, recognize a
more distal epitope in the 26–32 portion.8 These second-
generation assays were globally called ‘intact’ PTH assays as
they were thought to measure only the full-length 1–84 PTH.
Although producing far more clinically satisfying data than
first-generation assays (i.e., very low to very high values
instead of always high, and significant correlation with bone
biopsy parameters in CKD patients; clearly low values in
‘non-parathyroid hypercalcemia or hypoparathyroidism),
they were rapidly shown to present some limitations. In
particular, several reports suggested that they overestimated
the degree of secondary hyperparathyroidism in CKD
patients,14,15 leading to an increased effort to suppress PTH
with its consequent concern for the development of
adynamic bone disease and erroneous referrals for parathyr-
oidectomy. Indeed, it was not understood why a hemodialysis
patient with histological features of low-turnover bone
disease may have an ‘intact’ PTH concentration as high as
400–500 pg/ml. One possible explanation came from the
demonstration that several ‘intact’ PTH assays recognized
with various cross-reactivities (from approximately 50 to
100%) a PTH molecule, different from 1–84 PTH, which
co-eluted in high-performance liquid chromatography
with a synthetic 7–84 PTH fragment.16 In 1999, the first
third-generation PTH assay was developed by Scantibodies
Laboratories.17 This immunoradiometric assay, called Whole
PTH assay, uses an anti C-terminal antibody similar to that
of the ‘intact’ PTH assays, but an anti N-terminal antibody
directed against the very first amino-acids (1–4), and, thus,
does not measure the 7–84 PTH.18 Although highly correlated
to the Allegro ‘intact’ assay, it was shown to produce lower
serum concentrations (approximately 50%) but similar
values in solutions of synthetic full-length 1–84 PTH.18 It
was, thus, believed that when serum PTH is measured with
these two assays, the difference between the two measured
values corresponds to the concentration of 7–84 PTH.
Assuming this, it was shown that the percentage of 7–84
PTH increases when the glomerular filtration rate dec-
reases,19 and is variable from one patient to another.20 Since
then, several studies have demonstrated that, in animal or
cellular models, 7–84 PTH exerts effects that are opposite to
those of 1–84 PTH (decrease in serum calcium and urine
phosphate, inhibition of bone resorption), and is produced
by the parathyroid glands in response to an increase in serum
calcium levels.21,22 There is now convincing evidence that
these inhibitory effects of the 7–84 PTH fragment are
mediated through a receptor different of the PTH/PTHrP
receptor (PTHR1) as reviewed in23 and through a desensi-
tization of PTHR1 in some cells.24
An important question is whether the third-generation
PTH assays improve the detection of altered bone turnover
compared with the second-generation assays. To answer this
question, bone biopsy studies are necessary. To date, four
studies have addressed this question for dialysis patients with
bone biopsies. In the first one,25 it was found that the ratio
1–84 PTH/7–84 PTH (obtained by measuring PTH with two
different assays, a second- and a third-generation assay)
discriminated between high- and low-turnover bone disease
significantly better than PTH measured by either a second- or
third generation assay alone. However, the three other
studies26–28 did not find any improvement in the diagnosis
of bone turnover anomalies with either this ratio or the
third-generation PTH alone compared with a second-
generation assay. As treatment with active vitamin D may
greatly modify the relationship between histomorphometric
indices of bone turnover and PTH levels, it must be stressed
that the patients studied in these four studies differed in
terms of past or actual vitamin D therapy, and that this may
represent a possible explanation for the discrepancies
between these studies. Another aspect, which should be
controlled in such studies, is the ethnic origin of the enrolled
patients. Indeed, it has been shown that second-generation
PTH levels correlated with bone turnover indexes in
Caucasian but not African-American dialysis patients.29
Furthermore, in CKD African-American patients, the PTH
levels are usually found to be higher than those in Caucasians
despite near-similar levels of bone alkaline phosphatise,
suggesting that optimal bone turnover may be associated
with different levels of PTH in these two ethnic groups.
Nevertheless, even if the group of experts who published the
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K/DOQI guidelines acknowledged the potential advantage of
the third-generation PTH assays, they recommended mea-
suring PTH in CKD patients by means of a second-
generation assay until more definitive bone biopsy studies
have been published.4,30 However, besides the evaluation of
altered bone turnover, other outcomes may be considered
when comparing the relative merits of both generations of
PTH assays. In a recent publication31 for example, a third-
generation PTH assay (but not a second-generation assay, or
the 1–84 PTH/7–84 PTH ratio) was predictive of all-cause
mortality in a cohort of incident dialysis patients. We,
thus, think, like the experts of the K/DOQI group, that
further research on the third-generation assays is mandatory,
but that there is currently no need to ask the laboratory
to switch from a second-generation to a third-generation
PTH assay.
Finally, it should also be mentioned that a new PTH
species called amino-PTH (N-PTH), measured with the
Whole PTH assay (third-generation assay) and the Elecsys
assay (second-generation, which uses an anti 26–32
N-terminal antibody), but not with an ‘intact’ PTH assay,
which used an anti 15–20 N-terminal antibody, has been
described recently, a finding, which adds more complexity to
this already highly complicated topic.32 Even if its exact
structure is still unknown, N-PTH should, thus, contain the
1–4 amino-acids, but should be different from the 1–84 PTH
in the 15–20 portion of the molecule. Whereas the amount
of N-PTH is approximately one-tenth of that of 1–84 PTH
in normal subjects,32 it has been shown to be excessively
produced in rare patients with either a parathyroid
carcinoma33,34 or a severe primary hyperparathyroidism.35
In these patients, the PTH concentration measured with a
third-generation assay was higher than when measured with a
second-generation assay with a proximal (15–20) epitope.
This atypical profile became normal (second-generation
higher than third-generation PTH) after parathyroidectomy
in patients with either primary hyperparathyroidism35 or
parathyroid cancer,34 suggesting that it was produced by the
abnormal glands. Table 1 and Figure 1 summarize what the
different PTH immunoassays measure. This table also
highlights the need for a revision of the nomenclature of
the different PTH molecules and PTH assays. Indeed, when
one understands that the ‘intact’ assays do not measure only
the intact PTH molecule, whereas BioIntact assay measures
the intact molecule and another molecule whose biological
activity is unknown, one can imagine the confusion for the
nonspecialist.
ANALYTICAL AND PRE-ANALYTICAL PROPERTIES OF THE PTH
ASSAYS
The second- and third-generation assays are overall of good
analytical quality with within-run and inter-day coefficients
of variation typically in the range of 1 to 10%, automated
assays giving generally moderately lower coefficients of
variation than manual assays. It is important that the chosen
assay presents a detection limit that is sufficiently low to
avoid overlap with low-normal values, say at least below
3–5 pg/ml. From the pre-analytical point of view, serum PTH
measured either with the second-36 or third-generation
assays18 have been shown to be stable when serum is left
standing at room temperature for up to 6 h before being
frozen. For longer delay, PTH seems slightly more stable in
ethylenediaminetetraacetic acid (EDTA) plasma or in serum
kept at þ 4 1C.37 However, if EDTA sampling tubes are used
instead of dry tubes, it should be kept in mind that EDTA
PTH values may be higher than serum values by 10–30%
depending on the assay used.36–39 There is no clear
explanation for this phenomenon, but the most probable
one is a calcium dependency of the epitope recognized by
some antibodies. It is, thus, important to verify that the
reference values have been established with the correct
samples. Furthermore, compared with EDTA plasma, serum
samples have the advantage to allow calcium measurement
and to be valid even in poorly filled tubes (see Table 2 for the
relative advantages of serum or EDTA samples). Finally, PTH
concentration is not affected by four18,39 or even six40
freeze–thaw cycles.
A constant finding when comparing different immunoas-
says is that, although the values obtained from different
assays are generally highly correlated, absolute concentration
may greatly differ. As suggested above, this may be due
to differences in cross-reactivity with 7–84 PTH. However,
PTH assays also suffer a lack of standardization as evidenced
by D’Amour et al.8 The only International Reference
Table 1 | The main circulating fragments of PTH, and whether they are measured (Yes) or not (No) by the various PTH assay
generations
First-generation assays Second-generation assays Third-generation assays
Most common identifications C-PTH assays, Mid-PTH assays ‘Intact’ PTH assays Whole PTH assay, Ca-PTH assay,
BioIntact PTH assay
Methodology Competition (mostly RIA) Immunometry (‘sandwich’ assays) Immunometry (‘sandwich’ assays)
1–84 PTH Yes Yes Yes
7–84 PTH Yes Yes (with various cross-reactivity) No
C-terminal fragments Yes No No
‘Amino’ PTH Yes Depends on the epitope of the anti-N-terminal
Ab: No if the epitope is proximal (13–24) and
Yes if the epitope is distal (26–32)
Yes
Ab, antibody; Ca-PTH, calcium-PTH; PTH, parathyroid hormone; RIA, radioimmunoassay.
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Preparation for PTH immunoassays, identified as WHO79/
500, was prepared in 1981 with purified human PTH.41 To
our knowledge, few of the currently used PTH assays have
been calibrated against this standard. Most assays are
calibrated against synthetic 1–84 PTH from various origins,
and there is currently no recognized international standard
made of synthetic PTH. If such a standard becomes available,
a possible matrix effect,42 that is the influence of the diluent
(protein concentration, pH, ionic compositiony) on the
measured concentration of a given amount of the analyte
diluted in a given volume of different diluents, and
the instability of synthetic PTH over extended storage
periods43 should be taken into account in the calibration
procedure.
LACK OF STANDARDIZATION OF PTH ASSAYS:
CONSEQUENCES AND HOW TO MANAGE THEM
It is worth noting that the K/DOQI target ranges were
initially established during the early 1990’s44 when bone
biopsy data from dialysis patients were compared with PTH
concentrations measured with the Allegro intact PTH assay
(the only so-called ‘intact’ PTH assay available at that time).
However, we36,45 and others46 have recently reported a
marked, and sometimes clinically significant, inter-method
variability in PTH measurement in CKD patients. Indeed,
with some assays the measured concentrations were markedly
different from those measured with the Allegro intact PTH
assay so that many patients were classified differently
according to the K/DOQI target ranges, inducing potentially
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Figure 1 |Amino-acid sequences. 1–84 PTH (a), 7–84 PTH (b), and N-PTH (c). Both second- and third-generation PTH assays use two
antibodies directed toward different epitopes. In both generations of assays, the capture antibody (coated to a solid phase) is directed
toward the 39–84 portion of the PTH molecule. In the Ca-PTH (third generation) assay, the labeled antibody recognizes the 1–4 portion
and, thus, may bind to both 1–84 PTH and N-PTH, but not to the 7–84 PTH (as the 1–4 amino acids of the 1–84 PTH are absent). In most
second-generation assays, the labeled antibody is directed toward the 15–20 portion of the 1–84 PTH molecule and, thus, may bind to both
1–84 PTH and 7–84 PTH, but not to the N-PTH (as, probably, the Ser17 of the 1–84 PTH is phosphorylated, which prevents binding
of the labeled antibody). In some second-generation assays (such as the Roche assay), the labeled antibody is directed toward the 26–32
portion of the 1–84 PTH molecule and, thus, may bind to 1–84 PTH, 7–84 PTH, and N-PTH.
Table 2 | Summary of the advantages/disadvantages of serum and EDTA plasma as the sample of choice for the measurement
of PTH in CKD patients
Serum EDTA
Stability of PTH during 4 h at RT Good Good
Stability of PTH during 18 h at RT Concentration does not change or
decreases by up to 20% (usually less)
Concentration does not change or
increases by up to 12% (usually less)
Stability of PTH during 24 h at 4 1C Good Good
Possibility to measure calcium in the same sample Yes No
Necessity to fill the tube sufficiently (450%) No Yes
Necessity to delay centrifugation to allow blood to clot Yes No
Ab, antibody; Ca-PTH, calcium-PTH; CKD, chronic kidney disease; EDTA, ethylenediaminetetraacetic acid; PTH, parathyroid hormone; RIA, radioimmunoassay; RT, room
temperature.
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different therapeutic options. As this situation is unaccep-
table, standardization of PTH results is mandatory.47 This is,
however, not easy to achieve because the Allegro intact PTH
assay is no longer available since late 2005/early 2006 and,
thus, cannot be used as the reference for PTH measurement
anymore. Furthermore, several new assays, not clearly
compared with the Allegro assay, became available since
2006. Such standardization necessitates a close cooperation
between kit manufacturers, physicians, and clinical chemists,
as well as a consensus from an expert panel regarding the best
procedure to apply.
The first option to standardize PTH results would be to
calibrate all existing assays against a unique International
Reference Preparation made of recombinant 1–84 PTH. As
underlined above, such a standard does not exist. Further-
more, it is now clear that the various second-generation PTH
assays demonstrate different cross-reactivities (50–100%)
with 7–84 PTH and other N-truncated fragments.16,45 In
dialysis patients, these fragments are approximately as
abundant as 1–84 PTH.19 It is, thus, likely that, even if a
perfect calibration against a unique international standard
made of recombinant 1–84 PTH is achieved with every PTH
kit (i.e., all assay produce the expected concentration in a
solution containing a known amount of the standard
preparation), the serum concentrations measured in dialysis
patients will be still different from one assay to another by an
average of 25% (higher values with assays that measure 100%
7–84 PTH than with those that measure only 50%).
Another way to standardize PTH results would be to use
exclusively third-generation PTH assays that do not cross-
react with 7–84 PTH and related fragments. After all, even if
these third-generation assays have not been shown to give
better clinical information than the second-generation assays,
there is no evidence that they provide poorer information.
However, as the third-generation assays give lower values
than the second-generation assays, the target values would
need to be revisited. Furthermore, the only third-generation
assay currently available18 is a manual immunoradiometric
assay, and is, thus, not practicable in most routine clinical
laboratories on the one hand and is more time-consuming
(overnight incubation) than the automated assays, inducing
potentially a delay in obtaining a result on the other hand.
Without definitive recommendation for the standardiza-
tion of PTH assays and waiting for an updating of the
K/DOQI recommendations regarding PTH measurement in
CKD patients, a pragmatic approach to limit inter-assay
discrepancies is urgently needed. As all PTH assays (even
those displaying various cross-reactivities with 7–84 PTH) are
satisfactorily correlated with each other on the whole range of
concentrations, a simple method would be to apply a
correction factors to the results produced by some assays.
The first step would be to identify from previous studies45,46
the assays that produced results similar to those of the
Allegro intact PTH assay and that could, thus, be regarded as
alternative reference assays. The second step would be to
compare one of these alternative reference assays with any,
not yet sufficiently characterized, other PTH assay. If the
tested assay produces concentrations that are sufficiently
different (i.e., 15–20% or more) from those of the reference
assay, then a correction factor may be calculated. To be
acceptable, this correction factor must be highly reproducible
when derived from comparison of these two assays
performed in different laboratories (at least 3 for each assay)
with different lots of reagents and for different groups of
patients (same grade of CKD). As an example, we recently
compared the Elecsys PTH assay manufactured by Roche
Diagnostics and previously shown to produced results similar
to those of the Allegro assay,46,47 with the Architect PTH
assay manufactured by Abbott Diagnostics, for 216 dialysis
patients.48 We found that the Architect PTH assay yielded
values that were 1.3 times higher than those provided by the
Elecsys PTH assay. The ratio between the Architect and the
Elecsys PTH values was quite similar among patients and was
highly reproducible among different lots of reagents used in
three different laboratories and for three different groups of
dialysis patients. We, thus, calculated ‘corrected’ Architect
values by dividing the measured values by 1.3. Of note is the
fact that almost one-quarter (53/216) of the patients tested in
this study were initially classified differently with the two
assays according to the K/DOQI target ranges and might
have, thus, received different treatments (more PTH-lowering
treatments such as active vitamin D compound or calcimi-
metic agents when the Architect assay is used), whereas only
less than 3% (6/216) remained classified differently after
correction of the Architect concentrations.
However, as underlined above, the use of correction
factors to overcome the inter-method variability of PTH
measurement is not a panacea and must be considered only
as a pragmatic approach to minimize the problem (better
than doing nothing). It is not fully satisfying and, in
particular, does not take into account the variable propor-
tions of 1–84 PTH versus PTH fragments and the various
cross-reactions for 7–84 PTH from one second-generation
assay to another.45 Note, however, that third- and second-
generation assays, although measuring (by definition)
different PTH molecules, are highly correlated. Another
approach would be to persuade the kit manufacturers to
provide biological correlates for their kits and clear indica-
tion on their cross-reactivities for the different PTH
molecules. Indeed, in contrast to the invention of new drugs,
any assay can just be put on the market without any
validation of its biological significance, assuming that an
analytical evaluation has been performed. In the defense of
these companies, we must highlight that no recommendation
currently exist.
CONSEQUENCES OF PTH MEASUREMENTS IN CLINICAL
SETTINGS: THE FRENCH NATIONAL PHOSPHORUS AND
CALCIUM OBSERVATORY
To illustrate some of these points, we present PTH
measurements from the French National Phosphorus and
Calcium Observatory, the largest prospective European
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mineral and bone disease data collection in maintenance
dialysis patients. More than 9000 patients were sampled
across 19 geographical regions in France, representing
approximately 30% of the total population of dialysis
patients in France. The database provides detailed patient-
specific information including demographic data, comorbid-
ities, 25 clinical and biological parameters, and medication
use. Laboratory values, including serum levels of calcium,
phosphorus, and PTH, and prescribed medications, are
collected at baseline and at 6-month intervals.
Here we report the cross-sectional analysis of data of 9,169
prevalent maintenance hemodialysis (MHD) patients col-
lected in June 2008. There was no centralized laboratory
measurement in the study. All parameters were measured on
a routine basis according to local setups for each facility. PTH
assays were recorded; in each dialysis facility the same kit was
used for all patients. PTH measurement was available for
7,004 patients. Detailed measurements kits were available for
5,611 patients (Table 4).
Parathyroid hormone levels were measured using nine
different kits as shown in Table 4. According to the variability
from the Allegro intact PTH reference values, correcting
factors suggested in Table 3 and derived from previous
publications by us were applied. We must underline that,
except for the Architect assay,48 the correction factors
proposed here are derived from single-center studies and
may, thus, be slightly different if tested in several laboratories.
At least, the ratio tested kit/reference’ kit was quite similar
(within±30% from the mean ratio) among patients. We
must also say that these ratios were derived from a French
population of dialysis patients and may, thus, not be
generalized to other populations of dialysis patients (i.e.,
African American) or to patients with different stages of
CKD. Raw and corrected values are presented in Table 4. We
then classified patients according to the K/DOQI PTH target
range, for example, a serum PTH (i) lower than 150 pg/ml,
(ii) equal to or greater than 150 and lower than 300 pg/ml,
and (iii) equal to or greater than 300 pg/ml, before and after
correction (Table 5).
The results show that approximately 17% of patients
might have been misclassified, and this raises the question
whether routine corrections should be performed. Indeed, 61
patients out of 2612 (2.3%) with low serum PTH entered the
‘normal’ range, whereas 138 (5.3%) patients classified as
‘normal’ before correction entered the ‘low’ PTH range after
correction. Ninety-one patients (3.5%) considered having
normal PTH level were found in the upper group after
correction, whereas 143 (5.5%) with a diagnosis of
hyperparathyroidism were in fact in the ‘normal’ range after
correction. Such misclassification might have elected patients
for inadequate treatments in almost one over five patients.
CONCLUSION
This paper summarizes the current state-of-the art (or closer
to the reality of the topic, the current ‘state of uncertainty’)
regarding the PTH measurement in CKD. It clearly shows a
large variability among PTH measurement kits and potential
limits of this measure. Since some recommendations from
the K/DOQI guidelines are based on serum PTH levels,
clarification appears mandatory and rapidly advisable. Until
a common standard becomes available, correction of some
measurement kits could be made, introducing more com-
plexity to an already complicated therapeutic field. However,
Table 3 | Proposed correcting factors for PTH results based on
previous publications36,45,48
No correction:
Bayer PTH Advia Centaur36,45
Access Intact PTH (Beckman Coulter)36
Roche Elecsys PTH45
Schering CisBio ELSA45
Scantibodies Total Intact PTH45
Divide by following factor:
Architect PTH Abbott: /1.348
Beckman Coulter PTH IRMA: /1.245
DiaSorin Intact PTH IRMA: /0.5545
LIAISON N-tact PTH: /0.9045
Scantibodies Ca-PTH IRMA: /0.55 (the only third-generation assay)45
Special case:
DPC Immulite 2000 intact PTH36
If in serum, no change; if in plasma, divide by 1.25
Ca-PTH, calcium-PTH; ELISA, enzyme-linked immunosorbant assay; IRMA, immuno-
radiometric assay; PTH, parathyroid hormone.
Table 4 | Effect of correcting PTH values in the French
National Phosphorus and Calcium Observatory (June 2008
values) according to the measurement kit; correcting factors
suggested in Table 3 were applied to raw PTH values.
Kit n Raw values Corrected
1 Architect PTH Abbot 684 397.6±359.4 305.8±276.4
2 Bayer PTH Advia Centaur 652 342.3±363.7 No correction
3 Beckman Coulter PTH IRMA 268 326.6±314.4 272.2±262.0
4 DPC Immulite 2000 intact PTH 542 316.7±306.0 253.3±244.8
5 DiaSorin Intact PTH IRMA 165 271.1±222.2 492.9±403.9
6 DiaSorin LIAISON N-tact PTH 953 320.8±284.7 356.5±316.4
7 Access Intact PTH
(Beckman Coulter)
107 404.6±329.3 No correction
8 Roche Elecsys PTH 1958 307.4±297.4 No correction
9 Scantibodies Total Intact PTH 282 238.8±197.3 No correction
IRMA, immunoradiometric assay; PTH, parathyroid hormone.
Table 5 | Number of patients classified within three PTH
targets before and after correction in 2612 patients: 2179
patients did not change categories, whereas 433 (17%) could
have been misclassified
Corrected PTH
PTH (pg/ml) o150 150–300 X300
Raw PTH
o150 672 61 0
150–300 138 549 91
X300 0 143 958
PTH, parathyroid hormone.
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even if this problem of standardization of PTH kits is solved,
a PTH concentration measured in a dialysis patients will still
be a far from perfect surrogate marker of bone turnover.
Association of PTH measurement with one bone marker
such as bone alkaline phosphatase may improve the diagnosis
of altered bone turnover, but needs extensive evaluation to
provide recommendations for their use in clinical practice.
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